hypotensive effect of amla ( Emblica officinalis)

Comparison of the hypotensive effect of amla ( Emblica officinalis) and placebo in patients with essential hypertension

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090527001957N7

Enrollment

Registered

2018-03-23

Start date

2017-10-01

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Intervention group: Amla capsule( 500 mg) 3 times/day after meal. Intervention 2: Control group: placebo capsul 3 times /day after meal.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: SBP>=140 mmHg SBP>=150 mmHg in 60 year old or older patients DBP>=90 mmHg

Exclusion criteria

Exclusion criteria: SBP>180 mmHg DBP>110 mmHg secondary hypertension hypertensive encephalopathy Hypertensive retinopathy grade 3,4 Acute cerebrovascular accident Acute coronary syndrome decompensated congestive heart failure creatinin > 1.5 times more than normal limit ALT> 3 times more than normal limit diabetic complications coagulopathy use of anticoagulants and anti platelet drugs use of NSAIDS platelet<100000

Design outcomes

Primary

Measure	Time frame
Systolic blood pressure. Timepoint: before the intervention, at the end of the first and second month after intervention. Method of measurement: mercury barometer.;Diastolic blood pressure. Timepoint: before the intervention, at the end of the first and second month after intervention. Method of measurement: mercury barometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFataneh Hashem-Dabaghian

Research Institute for Islamic and Complementary Medicine

fataneh.dabaghian@yahoo.com+98 21 3395 0154

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026